Ireland Reimburses Medical Marijuana-Based Drug For Chemotherapy-Induced Nausea And Vomiting

Althea Group Holdings Limited AGH, an Australian manufacturer of cannabis-based medicines and recreational cannabis products confirmed that Ireland’s Primary Care Reimbursement Service (‘PCRS’) has approved Althea THC20:CBD1 cannabis oil for reimbursement in Ireland. The company’s subsidiary, MyAccess Clinics, a private medical clinic specializing in medicinal cannabis, will offer consultations to patients in Ireland beginning in November.

The news comes on the heels of Ireland’s Citizens Assembly on Drugs Use voting in favor of a new health-led approach to drugs and illegal substances.

Althea THC20:CBD1 has now been added to the PCRS in Ireland, making it free of charge for Irish patients being treated for intractable nausea and vomiting associated with chemotherapy (CINV). The agreed reimbursement price for the company’s marijuana oil is €330 ($350).

“The addition of Althea THC20:CBD1 to the Primary Care Reimbursement Service in Ireland is another remarkable achievement for Althea and solidifies our position as the global leader in the sale and distribution of medicinal cannabis extracts,” stated Joshua Fegan CEO of AGH. “MyAccess Clinics has already serviced thousands of patients in the UK, and we look forward to offering an excellent service to our deserved patients in Ireland.”

MyAccess Clinics

MyAccess Clinics’ healthcare professionals will be available to consult with Irish patients whose prescriptions can be filled electronically and medicines delivered by mail. The Irish expansion will utilize existing infrastructure and does not require any additional capital expenditure.

Jazz’ Sativex Aslo Reimbursed

Earlier this month, MS Ireland, which is the national organization providing information, services and support to people with multiple sclerosis in Ireland confirmed there will be reimbursement for Sativex.

Under the Managed Access Program, Sativex is available for reimbursement for treating moderate-to-severe spasticity in adult MS patients who have not responded to other anti-spasticity medications.

Sativex (also known as nabiximols) was given the green light by the NHS in 2019 to treat MS-linked muscle spasms. The drug, initially developed by GW Pharmaceuticals which is now part of Jazz Pharmaceuticals JAZZ, is a mix of equal parts of the psychoactive substance Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) that helps reduce pain, inflammation and anxiety without psychoactive effects.

Reimbursement is supported on an individual basis through Ireland's Health Service Executive (HSE) - Primary Care Reimbursement Service (PCRS) online application system. High Tech prescriptions generated on the High Tech Hub (HTH) will be eligible for reimbursement. The program began Oct.1.

Did you miss the first wave of cannabis investments? Don’t make that mistake again.
Experts believe cannabis stocks have found their floor and are now poised for unprecedented growth.
Join Benzinga PotProfits. Our in-house canna stock expert, Michael Berger, is on a mission to uncover the most promising cannabis stocks poised for growth, even in a dull market. He leaves no bud unturned to bring you the juiciest potential double-digit opportunities!
Just this year, the PotProfits portfolio has seen smoking-hot gains like:

47.10% with $GTBIF
40.23% with $TCNNF
21.50% with $VFF

But here’s the kicker: Michael is about to release his next potential winners, and he’s chomping at the bit to share these ticker symbols with you ASAP.Don’t miss out on the green rush!

Photo: Benzinga edit with images by Alejandro Luengo and Jose Luis Sanchez Pereyra via Unsplash

Market News and Data brought to you by Benzinga APIs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Zinger Key Points

MyAccess Clinics

Jazz’ Sativex Aslo Reimbursed

The Benzinga Cannabis Capital Conference is coming to Florida